XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for:
•
Rheumatoid Arthritis: XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
•
Psoriatic Arthritis: XELJANZ/XELJANZ XR is indicated for the
treatment of adult patients with active psoriatic arthritis who have had an
inadequate response or intolerance to one or more TNF blockers.
•
Ankylosing Spondylitis: XELJANZ/XELJANZ XR is indicated for the
treatment of adult patients with active ankylosing spondylitis who have
had an inadequate response or intolerance to one or more TNF blockers.
•
Ulcerative Colitis: XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers.
•
Polyarticular Course Juvenile Idiopathic Arthritis: XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers.
